---
document_datetime: 2024-10-25 12:18:43
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/suliqua-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: suliqua-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.528318
conversion_datetime: 2025-12-27 13:17:18.781277
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Suliqua

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0044            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 22/10/2024                          |                                             | SmPC and PL                      |           |
| WS/2732              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. | 17/10/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                      |            |            |             |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| N/0042              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                    | 13/09/2024 |            | PL          |                                                                                                                                            |
| PSUSA/10577 /202311 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                       | 27/06/2024 | 22/08/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10577/202311. |
| IB/0039/G           | This was an application for a group of variations. B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation B.I.c.2.z - Change in the specification parameters and/or limits of the immediate packaging of the AS - Other variation                                                  | 26/02/2024 | n/a        |             |                                                                                                                                            |
| II/0037/G           | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.d - Change in the batch size (including batch | 15/02/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                             |            |     |                             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------|
| IA/0041/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where place | 01/02/2024 | n/a | batch control/testing takes |
| WS/2570   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                            | 18/01/2024 | n/a |                             |
| WS/2539   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                        | 07/09/2023 | n/a |                             |

<div style=\"page-break-after: always\"></div>

| N/0035              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/07/2023   | 06/06/2024   | PL          |                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10577 /202211 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/06/2023   | n/a          |             | PRAC Recommendation - maintenance                                                                                                                                                                                              |
| IB/0033             | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/05/2023   | n/a          |             |                                                                                                                                                                                                                                |
| WS/2418             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (uncommon). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 04/05/2023   | 06/06/2024   | SmPC and PL | The Product Information is updated to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency uncommon. For more information, please refer to the Summary of Product Characteristics. |
| IA/0032/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                  | 03/03/2023   | n/a          |             |                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        |                               |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------|
| T/0028      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/11/2022 | 09/12/2022 | SmPC, Labelling and PL |                               |
| IA/0029/G   | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 01/12/2022 | n/a        |                        |                               |
| PSUSA/10577 | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/06/2022 | 22/08/2022 | SmPC and PL            | Please refer to Suliqua EPAR: |

<div style=\"page-break-after: always\"></div>

| /202111   | insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  | Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------|
| IA/0027   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                         | 10/03/2022 | n/a        |                                  |                                                                                                             |
| II/0024   | Submission of the final Clinical Study Report of the Category 3 PASS INSLIC08571, a 'Survey to evaluate the knowledge and understanding of the key safety messages in the healthcare professional guide and the patient guide'. The provision of the final survey results addresses post-authorisation measure (PAM) MEA 002.7. The updated RMP version 6.1 was agreed during the procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 13/01/2022 | n/a        |                                  | n/a                                                                                                         |
| IB/0025   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                  | 06/01/2022 | 22/08/2022 | SmPC and PL                      |                                                                                                             |
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/09/2021 | 22/11/2021 | SmPC, Annex II, Labelling and PL |                                                                                                             |
| II/0023   | Submission of the final study report from the 'Patient registry of lixisenatide use in adult type 2 diabetes',                                                                                                                                                                                                                                                                                                                                                                                       | 02/09/2021 | n/a        |                                  | n/a                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | which is included as a Category 3 PASS in the RMP. This study's objective is to monitor the occurrences of events of interest including acute pancreatitis, pancreatic cancer and thyroid cancer, especially medullary carcinoma of the thyroid (MCT), among adult type 2 diabetes patients treated with Lixisenatide using the data from national registers and databases in Italy and Belgium. The provision of the study report addresses post-authorisation measure (PAM) MEA 005.3. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |    |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10577 /202011 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/06/2021 | n/a        |    | PRAC Recommendation - maintenance |
| PSUSA/10577 /202005 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/01/2021 | n/a        |    | PRAC Recommendation - maintenance |
| N/0020              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/11/2020 | 12/11/2021 | PL |                                   |
| IB/0017/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                            | 23/09/2020 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

| IG/1282             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                     | 15/09/2020   | n/a        |                       |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------|
| IA/0018/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                    | 03/09/2020   | n/a        |                       |                                   |
| IAIN/0015           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                         | 10/08/2020   | 12/11/2021 | SmPC, Annex II and PL |                                   |
| PSUSA/10577 /201911 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                          | 11/06/2020   | n/a        |                       | PRAC Recommendation - maintenance |
| WS/1819/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of | 05/06/2020   | n/a        |                       |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                                  |                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------|
| II/0011 | Extension of Indication to include 'treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors' based on the phase 3 Study EFC13794; a 26-week randomized, open- label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP- 1 receptor agonist and metformin (alone or with pioglitazone and/or SGLT2 inhibitors), followed by a fixed ratio combination single-arm 26-week extension period. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the contact details of the local representatives in Denmark, the Netherlands and Malta in the Package Leaflet and to implement minor editorial changes in the annexes. An updated RMP | 30/01/2020 | 09/03/2020 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Suliqua-H-C-4243-II- 0011' |

<div style=\"page-break-after: always\"></div>

|                     | version 4.1 was agreed during the procedure. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10577 /201905 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/12/2019 | 17/02/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10577/201905. |
| PSUSA/10577 /201811 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/06/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10577 /201805 | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 29/11/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IG/0999/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 20/11/2018 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or   |            |            |                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0007/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/09/2018 | 03/09/2019 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUSA/10577 /201801   | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                   | 06/09/2018   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| PSUSA/10577 /201707   | Periodic Safety Update EU Single assessment - insulin glargine / lixisenatide                                                                                                                                                                                                                                                                                                                   | 08/02/2018   | n/a        | PRAC Recommendation - maintenance   |
| IB/0005/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                    | 15/11/2017   | n/a        |                                     |
| II/0003/G             | This was an application for a group of variations. B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data) B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol | 14/09/2017   | 19/04/2018 | SmPC, Labelling and PL              |
| II/0002               | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                   | 09/06/2017   | n/a        |                                     |
| IAIN/0001             | B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the                                                                                                                                                                                                                                              | 30/03/2017   | 19/04/2018 | SmPC, Labelling and                 |

<div style=\"page-break-after: always\"></div>

| product information   | PL   |
|-----------------------|------|